The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment.
Adult
Black or African American
/ ethnology
Aged
Delivery of Health Care
/ organization & administration
Diffusion of Innovation
Feasibility Studies
Health Equity
Healthcare Disparities
Hepatitis C, Chronic
/ drug therapy
Humans
Implementation Science
Male
Medication Adherence
Middle Aged
Rural Health
United States
United States Department of Veterans Affairs
Health disparities
Health equity
Healthcare disparities
Implementation framework
Implementation research
Implementation science
Journal
Implementation science : IS
ISSN: 1748-5908
Titre abrégé: Implement Sci
Pays: England
ID NLM: 101258411
Informations de publication
Date de publication:
12 03 2019
12 03 2019
Historique:
received:
11
05
2018
accepted:
25
01
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
14
8
2019
Statut:
epublish
Résumé
Researchers could benefit from methodological advancements to advance uptake of new treatments while also reducing healthcare disparities. A comprehensive determinants framework for healthcare disparity implementation challenges is essential to accurately understand an implementation problem and select implementation strategies. We integrated and modified two conceptual frameworks-one from implementation science and one from healthcare disparities research to develop the Health Equity Implementation Framework. We applied the Health Equity Implementation Framework to a historical healthcare disparity challenge-hepatitis C virus (HCV) and its treatment among Black patients seeking care in the US Department of Veterans Affairs (VA). A specific implementation assessment at the patient level was needed to understand any barriers to increasing uptake of HCV treatment, independent of cost. We conducted a preliminary study to assess how feasible it was for researchers to use the Health Equity Implementation Framework. We applied the framework to design the qualitative interview guide and interpret results. Using quantitative data to screen potential participants, this preliminary study consisted of semi-structured interviews with a purposively selected sample of Black, rural-dwelling, older adult VA patients (N = 12), living with HCV, from VA medical clinics in the Southern part of the USA. The Health Equity Implementation Framework was feasible for implementation researchers. Barriers and facilitators were identified at all levels including the patient, provider (recipients), patient-provider interaction (clinical encounter), characteristics of treatment (innovation), and healthcare system (inner and outer context). Some barriers reflected general implementation issues (e.g., poor care coordination after testing positive for HCV). Other barriers were related to healthcare disparities and likely unique to racial minority patients (e.g., testimonials from Black peers about racial discrimination at VA). We identified several facilitators, including patient enthusiasm to obtain treatment because of its high cure rates, and VA clinics that offset HCV stigma by protecting patient confidentiality. The Health Equity Implementation Framework showcases one way to modify an implementation framework to better assess health equity determinants as well. Researchers may be able to optimize the scientific yield of research inquiries by identifying and addressing factors that promote or impede implementation of novel treatments in addition to eliminating healthcare disparities.
Sections du résumé
BACKGROUND
Researchers could benefit from methodological advancements to advance uptake of new treatments while also reducing healthcare disparities. A comprehensive determinants framework for healthcare disparity implementation challenges is essential to accurately understand an implementation problem and select implementation strategies.
METHODS
We integrated and modified two conceptual frameworks-one from implementation science and one from healthcare disparities research to develop the Health Equity Implementation Framework. We applied the Health Equity Implementation Framework to a historical healthcare disparity challenge-hepatitis C virus (HCV) and its treatment among Black patients seeking care in the US Department of Veterans Affairs (VA). A specific implementation assessment at the patient level was needed to understand any barriers to increasing uptake of HCV treatment, independent of cost. We conducted a preliminary study to assess how feasible it was for researchers to use the Health Equity Implementation Framework. We applied the framework to design the qualitative interview guide and interpret results. Using quantitative data to screen potential participants, this preliminary study consisted of semi-structured interviews with a purposively selected sample of Black, rural-dwelling, older adult VA patients (N = 12), living with HCV, from VA medical clinics in the Southern part of the USA.
RESULTS
The Health Equity Implementation Framework was feasible for implementation researchers. Barriers and facilitators were identified at all levels including the patient, provider (recipients), patient-provider interaction (clinical encounter), characteristics of treatment (innovation), and healthcare system (inner and outer context). Some barriers reflected general implementation issues (e.g., poor care coordination after testing positive for HCV). Other barriers were related to healthcare disparities and likely unique to racial minority patients (e.g., testimonials from Black peers about racial discrimination at VA). We identified several facilitators, including patient enthusiasm to obtain treatment because of its high cure rates, and VA clinics that offset HCV stigma by protecting patient confidentiality.
CONCLUSION
The Health Equity Implementation Framework showcases one way to modify an implementation framework to better assess health equity determinants as well. Researchers may be able to optimize the scientific yield of research inquiries by identifying and addressing factors that promote or impede implementation of novel treatments in addition to eliminating healthcare disparities.
Identifiants
pubmed: 30866982
doi: 10.1186/s13012-019-0861-y
pii: 10.1186/s13012-019-0861-y
pmc: PMC6417278
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Pagination
26Références
West J Nurs Res. 2015 Feb;37(2):217-35
pubmed: 24838492
Implement Sci. 2015 Apr 21;10:53
pubmed: 25895742
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Annu Rev Public Health. 2017 Mar 20;38:1-22
pubmed: 28384085
Clin Infect Dis. 2015 Sep 1;61(5):730-40
pubmed: 25987643
Ann Intern Med. 2017 Oct 3;167(7):499-504
pubmed: 28973196
Med Educ. 2010 Dec;44(12):1166-74
pubmed: 21091758
Med Care. 2017 Sep;55 Suppl 9 Suppl 2:S9-S15
pubmed: 28806361
Medicine (Baltimore). 2016 May;95(22):e3719
pubmed: 27258498
J Gen Intern Med. 2014 Dec;29 Suppl 4:904-12
pubmed: 25355087
Ann N Y Acad Sci. 2010 Feb;1186:5-23
pubmed: 20201865
Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):501-505
pubmed: 28468532
Am J Public Health. 2014 Sep;104 Suppl 4:S609-19
pubmed: 25100428
J Gen Intern Med. 2013 Oct;28(10):1268-78
pubmed: 23649787
Implement Sci. 2015 Nov 04;10:155
pubmed: 26537706
Am J Prev Med. 2012 Sep;43(3):337-50
pubmed: 22898128
Hepatology. 2020 Feb;71(2):686-721
pubmed: 31816111
Implement Sci. 2015 Aug 07;10:109
pubmed: 26249843
Adm Policy Ment Health. 2009 Jan;36(1):24-34
pubmed: 19104929
Health Educ Q. 1988 Winter;15(4):351-77
pubmed: 3068205
LGBT Health. 2016 Apr;3(2):122-31
pubmed: 26674598
Implement Sci. 2008 Feb 15;3:8
pubmed: 18279503
Psychiatr Serv. 2007 Dec;58(12):1591-4
pubmed: 18048562
J Gen Intern Med. 2002 Jun;17(6):477-86
pubmed: 12133164
Implement Sci. 2017 May 11;12(1):60
pubmed: 28494811
Implement Sci. 2014 Nov 30;9:178
pubmed: 25433494
Implement Sci. 2016 Mar 22;11:42
pubmed: 27000147
LGBT Health. 2015 Jun;2(2):140-6
pubmed: 26790120
J Gen Intern Med. 2010 Jul;25(7):682-7
pubmed: 20238204
Clin Epidemiol. 2013 May 31;5:163-72
pubmed: 23766659
Soc Sci Med. 2014 Feb;103:126-133
pubmed: 24507917
Ann Fam Med. 2013 Jan-Feb;11(1):43-52
pubmed: 23319505
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
MMWR Morb Mortal Wkly Rep. 2009 Feb 20;58(6):133-8
pubmed: 19229164
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Clin Infect Dis. 2016 Aug 1;63(3):291-9
pubmed: 27131869
BMC Health Serv Res. 2018 Sep 12;18(1):710
pubmed: 30208873
Implement Sci. 2017 Jun 21;12(1):77
pubmed: 28637486
J Gen Intern Med. 2013 Nov;28(11):1504-10
pubmed: 23576243
J Gen Intern Med. 2008 May;23(5):654-71
pubmed: 18301951
Transl Behav Med. 2013 Jun 1;3(2):200-210
pubmed: 23750180
Transl Behav Med. 2017 Sep;7(3):389-392
pubmed: 28884305
Infect Agent Cancer. 2016 May 16;11:24
pubmed: 27186235
PLoS One. 2012;7(11):e48448
pubmed: 23144885
Hepatology. 2005 Jan;41(1):88-96
pubmed: 15619249
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):213-8
pubmed: 15671808
J Health Psychol. 2013 Jun;18(6):762-72
pubmed: 23449678
Ann Behav Med. 2011 Oct;42(2):235-44
pubmed: 21638196
J Fam Pract. 1991 Feb;32(2):175-81
pubmed: 1990046
Child Dev. 1996 Oct;67(5):1891-914
pubmed: 9022222
Ann Intern Med. 2006 May 16;144(10):705-14
pubmed: 16702586
BMC Med Res Methodol. 2006 Nov 08;6:54
pubmed: 17092344
Am J Public Health. 2014 Sep;104 Suppl 4:S555-61
pubmed: 25100421
Health Serv Res. 2003 Apr;38(2):613-30
pubmed: 12785564
J Viral Hepat. 2015 May;22(5):489-95
pubmed: 25417805
Med Care. 2017 Sep;55 Suppl 9 Suppl 2:S16-S23
pubmed: 28806362
Implement Sci. 2012 Apr 11;7:30
pubmed: 22494428
Implement Sci. 2015 Feb 12;10:21
pubmed: 25889199
Implement Sci. 2016 Mar 10;11:33
pubmed: 27013464
Am J Public Health. 2006 Dec;96(12):2113-21
pubmed: 17077411
Am J Public Health. 2015 Oct;105(10):1960-4
pubmed: 26270298
CMAJ. 1995 May 1;152(9):1423-33
pubmed: 7728691
J Am Board Fam Med. 2016 Jan-Feb;29(1):156-60
pubmed: 26769889
Am Psychol. 2013 May-Jun;68(4):237-46
pubmed: 23688091
Am J Public Health. 2008 May;98(5):846-52
pubmed: 18382007
Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1219-1222
pubmed: 28857899